Form 4: Solid Biosciences Chief Regulatory Officer Reports Stock Transactions
SEC Form 4 Filing
Solid Biosciences' Chief Regulatory Officer, Jessie Hanrahan, reported the acquisition of 11,862 shares through restricted stock unit vesting and the sale of 4,610 shares to cover withholding taxes.
Summary
- Jessie Hanrahan, Chief Regulatory Officer of Solid Biosciences, reported transactions involving the company's stock.
- On December 2, 2024, 11,862 shares were acquired through the vesting of restricted stock units (RSUs).
- On December 3, 2024, 4,610 shares were sold at a price of $5.6014 per share.
- The sale was to cover withholding taxes related to the vesting of the RSUs and was not a discretionary trade.
- Following these transactions, Ms. Hanrahan directly owns 14,235 shares of Solid Biosciences stock.
Sentiment
Score: 5
Explanation: The document reflects routine stock transactions by a company officer, which is neither positive nor negative for the company's overall performance. It is a standard practice.
Industry Context
This is a routine filing related to stock transactions by a company officer, which is common in publicly traded companies. It reflects the standard practice of equity compensation and tax obligations.
Comparison to Industry Standards
- The vesting schedule of the restricted stock units, with 25% vesting annually over four years, is a common practice in the biotechnology industry.
- The sale of shares to cover withholding taxes is a standard procedure for employees receiving equity compensation.
- Similar transactions are regularly reported by officers and directors of publicly traded companies, such as those in the biotech sector like BioMarin Pharmaceutical or Vertex Pharmaceuticals.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are related to standard equity compensation practices.
- The sale of shares by the officer does not indicate any change in the company's fundamentals.
Key Dates
| Date | Description |
|---|---|
| 12/02/2022 | Date of grant for the restricted stock units. |
| 12/02/2024 | Date of restricted stock unit vesting and acquisition of 11,862 shares. |
| 12/03/2024 | Date of sale of 4,610 shares at $5.6014 per share. |
| 12/04/2024 | Date of filing of the Form 4. |
Keywords
Solid Biosciences, stock transaction, restricted stock units, insider trading, Form 4, Jessie Hanrahan, share sale, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.